Ayurvedic Pharma Pitch Deck & Business Plan

Esslon Pharma, an innovation-driven Ayurvedic pharmaceutical company, partnered with Team Flexbox to raise growth capital to advance clinical trials and commercialize Pyrexium DS: India’s first scientifically validated Ayurvedic antiviral formulation for dengue. Despite the prevalence of dengue, the challenge of this project was building investor confidence at the intersection of traditional medicine, modern science, and scalable healthcare delivery.

We helped with

Investor Pitch Deck & Scientific Narrative Translation

One-Pager

Detailed Business Plan Document

Financial Modelling

Government Grant Applications

‍

The Challenge

Dengue remains a massive global health problem, yet investors remain cautious about Ayurvedic and alternative medicine without strong scientific framing.

Esslon’s formulation had deep R&D backing, but the clinical data and regulatory pathway were too technical for most investors to easily evaluate.

The company needed to simultaneously demonstrate medical credibility, IP strength, and commercial scalability.

Esslon also aimed to access government innovation grants, which demanded precise documentation, compliance alignment, and outcome-driven narratives.

Strategic Approach

Established Esslon from an “Ayurvedic product company” to a science-led preventive healthcare and antiviral innovation platform.

Translated complex clinical research, validation studies, and AYUSH compliance into clear, investor-friendly visuals and narratives.

Developed a dual go-to-market strategy, covering domestic deployment and export-ready AYUSH opportunities for global markets.

Created a cohesive financial model mapping clinical trial progress, manufacturing scale-up, and commercialization timelines to capital requirements.

Prepared grant-ready documentation, including a concise one-pager and a detailed business plan, and supported applications to programs such as NIDHI-SSS, aligning Esslon with national innovation and public health priorities.